Advertisement
Singapore markets closed

  • Straits Times Index

    3,313.48
    +8.49 (+0.26%)
     

  • Nikkei

    38,787.38
    -132.88 (-0.34%)
     

  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     

  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     

  • Bitcoin USD

    66,879.28
    +1,736.60 (+2.67%)
     

  • CMC Crypto 200

    1,366.91
    -6.93 (-0.50%)
     

  • S&P 500

    5,296.11
    -0.99 (-0.02%)
     

  • Dow

    39,925.78
    +56.40 (+0.14%)
     

  • Nasdaq

    16,679.71
    -18.61 (-0.11%)
     

  • Gold

    2,414.10
    +28.60 (+1.20%)
     

  • Crude Oil

    79.62
    +0.39 (+0.49%)
     

  • 10-Yr Bond

    4.4180
    +0.0410 (+0.94%)
     

  • FTSE Bursa Malaysia

    1,616.62
    +5.51 (+0.34%)
     

  • Jakarta Composite Index

    7,317.24
    +70.54 (+0.97%)
     

  • PSE Index

    6,618.69
    -9.51 (-0.14%)
     

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

Amicus Therapeutics, Inc.
·1-min read
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.

PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.

  • Cowen 44th Annual Health Care Conference in Boston, MA, on Monday, March 4, 2024, at 11:10 a.m. E.T.

  • Leerink Partners 2024 Global Biopharma Conference in Miami, FL on Monday, March 11, 2024, at 3:20 p.m. E.T.

A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

ADVERTISEMENT

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G